GENERAL NUTRITION "ON TARGET" TO OPEN 500 U.S. STORES BY THE END OF 1996, the company said Oct. 30. GNC opened 148 stores in the third quarter (ended Oct. 12), of which half are company-owned and half are franchised. GNC operates a total of 2,887 stores worldwide; 1,767 are company-owned and 1,120 are franchised. The stores operate under the General Nutrition Center, Natures Food Centre, Health & Diet Centre, Nature's Fresh and Amphora names in all 50 states, Puerto Rico and 16 countries. GNC is a specialty retailer of vitamins, supplements, sports nutrition, personal care and other health-related products.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
